Table 1 Summary of the main features of the currently available tumor necrosis factor alpha inhibitors
From: Update on intravitreal anti-tumor necrosis factor alpha therapies for ocular disorders
Generic name (brand name) | Molecular weight (kDa) | Mechanism of action | Route of administration | Half-life (days) |
|---|---|---|---|---|
Etanercept (Enbrel) | 150 | TNF soluble decoy receptor | Subcutaneous injection | 4 to 6 |
Infliximab (Remicade) | 149 | Anti-TNF monoclonal antibody | Intravenous infusion | 8 to 10 |
Adalimumab (Humira) | 148 | Anti-TNF monoclonal antibody | Subcutaneous injection | 14 |
Golimumab (Simponi) | 150 to 151 | Anti-TNF monoclonal antibody | Subcutaneous infusion | 14 |
Certolizumab (Cimzia) | 91 | Pegylated anti-TNF monoclonal antibody | Subcutaneous injection | 14 |